Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3995
Single User License Price INR 274137
Corporate User License Price USD 11985
Corporate User License Price INR 822411
Site License Price USD 7990
Site License Price INR 548274
Request a Quote

Report Title

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018

Quote Request for License Type
License Type Price  
Single User License USD 3995
Site License USD 7990
Enterprise Wide License USD 11985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018


Quote Request for License Type
License Type Price  
Single User License USD 3995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018



Executive Summary

Dermatological Burns, Scars and Ulcers Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and discontinued products.

A pressure ulcer is an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition. There are six products in development for this indication.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of a finger when pressed (known as pitting edema), discoloration and darkening of the skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make the leg feel hard (known as lipodermatosclerosis), and small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche). There are 14 products in development for this indication.

A burn refers to damage to the body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, which increases with each degree of burn, red and swollen skin, blisters, and charred and blackened skin. Treatment includes antibiotics and pain relievers. There are 32 products in development for this indication.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red-to-purple fibrous tissue that over time usually becomes flatter and lighter in color. There are 20 products in development for this indication.

Molecular targets acted on by products in development for dermatological burns, scars and ulcers include integrins, interleukins and growth factors. Companies operating in this pipeline space include MediWound, Aegle Therapeutics and NovaLead Pharma.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Dermatological Burns, Scars and Ulcers Report Coverage 8

2.2 Pressure Ulcers - Overview 8

2.3 Venous Leg Ulcers (Crural Ulcer) - Overview 8

2.4 Burns - Overview 8

2.5 Scar - Overview 8

3 Therapeutics Development 9

3.1 Pressure Ulcers 9

3.2 Venous Leg Ulcers (Crural Ulcer) 11

3.3 Burns 15

3.4 Scar 21

4 Therapeutics Assessment 26

4.1 Pressure Ulcers 26

4.2 Venous Leg Ulcers (Crural Ulcer) 29

4.3 Burns 35

4.4 Scar 43

5 Companies Involved in Therapeutics Development 49

5.1 Pressure Ulcers 49

5.2 Venous Leg Ulcers (Crural Ulcer) 51

5.3 Burns 56

5.4 Scar 62

6 Dormant Projects 69

6.1 Pressure Ulcers 69

6.2 Venous Leg Ulcers (Crural Ulcer) 69

6.3 Burns 71

6.4 Scar 73

7 Discontinued Products 74

7.1 Pressure Ulcers 74

7.2 Venous Leg Ulcers (Crural Ulcer) 74

7.3 Burns 75

7.4 Scar 75

8 Product Development Milestones 76

8.1 Venous Leg Ulcers (Crural Ulcer) 76

8.2 Burns 86

8.3 Scar 100

9 Appendix 113

9.1 Methodology 113

9.2 Coverage 113

9.3 Secondary Research 113

9.4 Primary Research 113

9.5 Expert Panel Validation 113

9.6 Contact Us 114

9.7 Disclaimer 114

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Number of Products under Development for Pressure Ulcers 9

Figure 2: Number of Products under Development by Companies, Pressure Ulcers 10

Figure 3: Number of Products under Development for Venous Leg Ulcers (Crural Ulcer) 11

Figure 4: Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer) 12

Figure 5: Number of Products under Development for Burns 15

Figure 6: Number of Products under Development by Companies, Burns 16

Figure 7: Number of Products under Development for Scar 21

Figure 8: Number of Products under Development by Companies, Scar 22

Figure 9: Number of Products under Development by Universities/Institutes, Scar 23

Figure 10: Number of Products by Routes of Administration, Pressure Ulcers 26

Figure 11: Number of Products by Stage and Routes of Administration, Pressure Ulcers 27

Figure 12: Number of Products by Molecule Types, Pressure Ulcers 28

Figure 13: Number of Products by Stage and Molecule Types, Pressure Ulcers 28

Figure 14: Number of Products by Top 10 Targets, Venous Leg Ulcers (Crural Ulcer) 29

Figure 15: Number of Products by Stage and Top 10 Targets, Venous Leg Ulcers (Crural Ulcer) 30

Figure 16: Number of Products by Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer) 31

Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer) 31

Figure 18: Number of Products by Routes of Administration, Venous Leg Ulcers (Crural Ulcer) 32

Figure 19: Number of Products by Stage and Routes of Administration, Venous Leg Ulcers (Crural Ulcer) 33

Figure 20: Number of Products by Molecule Types, Venous Leg Ulcers (Crural Ulcer) 34

Figure 21: Number of Products by Stage and Molecule Types, Venous Leg Ulcers (Crural Ulcer) 34

Figure 22: Number of Products by Top 10 Targets, Burns 35

Figure 23: Number of Products by Stage and Top 10 Targets, Burns 36

Figure 24: Number of Products by Top 10 Mechanism of Actions, Burns 38

Figure 25: Number of Products by Stage and Top 10 Mechanism of Actions, Burns 38

Figure 26: Number of Products by Routes of Administration, Burns 40

Figure 27: Number of Products by Stage and Routes of Administration, Burns 40

Figure 28: Number of Products by Molecule Types, Burns 41

Figure 29: Number of Products by Stage and Molecule Types, Burns 42

Figure 30: Number of Products by Top 10 Targets, Scar 43

Figure 31: Number of Products by Stage and Top 10 Targets, Scar 43

Figure 32: Number of Products by Top 10 Mechanism of Actions, Scar 44

Figure 33: Number of Products by Stage and Top 10 Mechanism of Actions, Scar 45

Figure 34: Number of Products by Routes of Administration, Scar 46

Figure 35: Number of Products by Stage and Routes of Administration, Scar 46

Figure 36: Number of Products by Molecule Types, Scar 47

Figure 37: Number of Products by Stage and Molecule Types, Scar 48

1.1 List of Tables

Table 1: Number of Products under Development for Pressure Ulcers 9

Table 2: Number of Products under Development by Companies, Pressure Ulcers 10

Table 3: Products under Development by Companies, Pressure Ulcers 11

Table 4: Number of Products under Development for Venous Leg Ulcers (Crural Ulcer) 12

Table 5: Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer) 13

Table 6: Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer) 14

Table 7: Number of Products under Development for Burns 15

Table 8: Number of Products under Development by Companies, Burns 17

Table 9: Number of Products under Development by Universities/Institutes, Burns 18

Table 10: Products under Development by Companies, Burns 19

Table 11: Products under Development by Universities/Institutes, Burns 20

Table 12: Number of Products under Development for Scar 21

Table 13: Number of Products under Development by Companies, Scar 22

Table 14: Number of Products under Development by Universities/Institutes, Scar 23

Table 15: Products under Development by Companies, Scar 24

Table 16: Products under Development by Universities/Institutes, Scar 25

Table 17: Number of Products by Stage and Target, Pressure Ulcers 26

Table 18: Number of Products by Stage and Mechanism of Action, Pressure Ulcers 26

Table 19: Number of Products by Stage and Route of Administration, Pressure Ulcers 27

Table 20: Number of Products by Stage and Molecule Type, Pressure Ulcers 29

Table 21: Number of Products by Stage and Target, Venous Leg Ulcers (Crural Ulcer) 30

Table 22: Number of Products by Stage and Mechanism of Action, Venous Leg Ulcers (Crural Ulcer) 32

Table 23: Number of Products by Stage and Route of Administration, Venous Leg Ulcers (Crural Ulcer) 33

Table 24: Number of Products by Stage and Molecule Type, Venous Leg Ulcers (Crural Ulcer) 35

Table 25: Number of Products by Stage and Target, Burns 37

Table 26: Number of Products by Stage and Mechanism of Action, Burns 39

Table 27: Number of Products by Stage and Route of Administration, Burns 41

Table 28: Number of Products by Stage and Molecule Type, Burns 42

Table 29: Number of Products by Stage and Target, Scar 44

Table 30: Number of Products by Stage and Mechanism of Action, Scar 45

Table 31: Number of Products by Stage and Route of Administration, Scar 47

Table 32: Number of Products by Stage and Molecule Type, Scar 48

Table 33: Pressure Ulcers - Pipeline by EyeGene Inc 49

Table 34: Pressure Ulcers - Pipeline by Izun Pharmaceuticals Corp 49

Table 35: Pressure Ulcers - Pipeline by MimeTech Srl 50

Table 36: Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd 50

Table 37: Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc 51

Table 38: Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG 51

Table 39: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Daval International Ltd 52

Table 40: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Factor Therapeutics Ltd 52

Table 41: Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc 53

Table 42: Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc 53

Table 43: Venous Leg Ulcers (Crural Ulcer) - Pipeline by MallInckrodt Plc 54

Table 44: Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd 54

Table 45: Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd 55

Table 46: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB 55

Table 47: Burns - Pipeline by AlgiPharma AS 56

Table 48: Burns - Pipeline by Alliance Pharma Plc 56

Table 49: Burns - Pipeline by Amarantus Bioscience Holdings Inc 57

Table 50: Burns - Pipeline by CFM Pharma Holding BV 57

Table 51: Burns - Pipeline by Destiny Pharma Plc 58

Table 52: Burns - Pipeline by Energenesis Biomedical Co Ltd 58

Table 53: Burns - Pipeline by Madam Therapeutics BV 59

Table 54: Burns - Pipeline by MallInckrodt Plc 59

Table 55: Burns - Pipeline by MediWound Ltd 60

Table 56: Burns - Pipeline by Phagelux Inc 60

Table 57: Burns - Pipeline by Se-cure Pharmaceuticals Ltd 61

Table 58: Burns - Pipeline by Therapure Biopharma Inc 61

Table 59: Burns - Pipeline by USV Pvt Ltd 62

Table 60: Scar - Pipeline by Abzena Plc 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Abzena Plc

AlgiPharma AS

Alliance Pharma Plc

Altacor Ltd

Amarantus Bioscience Holdings Inc

BirchBioMed Inc

CardioVascular BioTherapeutics Inc

CFM Pharma Holding BV

Cotinga Pharmaceuticals Inc

CytoTools AG

Daval International Ltd

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

EyeGene Inc

Factor Therapeutics Ltd

FirstString Research Inc

GangaGen Inc

Izun Pharmaceuticals Corp

Kringle Pharma Inc

Madam Therapeutics BV

MallInckrodt Plc

MediWound Ltd

MimeTech Srl

Moerae Matrix Inc

NovaLead Pharma Pvt Ltd

Phagelux Inc

Pharmaxis Ltd

Promore Pharma AB

Resolys Bio Inc

RXi Pharmaceuticals Corp

Se-cure Pharmaceuticals Ltd

Synedgen Inc

Therapure Biopharma Inc

USV Pvt Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person